利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.021 秒)

    Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
    2.
    发明授权
    Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use 有权
    允许含有外源表位的重组假病毒的表达和分泌的多核苷酸，其生产和用途

    公开(公告)号：US09096868B2

    公开(公告)日：2015-08-04

    申请号：US12678046

    申请日：2008-09-12

    申请人： Qiang Deng ,  Marie-Louise Michel

    发明人： Qiang Deng ,  Marie-Louise Michel

    IPC分类号： C12N15/86 ,  C07K14/005 ,  A61K39/00

    CPC分类号： C12N15/86 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N2730/10122

    摘要： This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells.

    摘要翻译： 本发明提供了一种设计具有缺陷复制周期的病毒的新方法，其可以被野生型病毒共感染拯救，并且其表达有助于消除病毒感染的细胞然后进行病毒清除的外来抗原表位 。 本发明的载体通过表达来自常见病原体的表位，绕过病毒特异性T细胞应答的现有耐受性。 载体只会在病毒感染的细胞中复制。

    Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
    5.
    发明申请
    Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis 失效
    核苷酸载体，含有该载体的组合物和用于免疫肝炎的疫苗

    公开(公告)号：US20090093428A1

    公开(公告)日：2009-04-09

    申请号：US11978673

    申请日：2007-10-30

    申请人： Marie-Louise Michel ,  Maryline Mancini

    发明人： Marie-Louise Michel ,  Maryline Mancini

    IPC分类号： A61K48/00 ,  A61P31/12

    CPC分类号： A61K39/292 ,  A61K39/00 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C12N2730/10122 ,  C12N2730/10134

    摘要： Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers.

    摘要翻译： 含有此类载体的核苷酸载体组合物和用于免疫肝炎的疫苗。 包含编码至少一部分病毒的至少一个基因或一个互补DNA的核苷酸载体和提供在肌肉细胞中表达该基因的启动子。 该基因可能是乙型肝炎病毒的S基因。 当向甚至慢性HBV携带者施用时的核苷酸载体组合物能够破坏对乙型肝炎病毒的表面抗原的T细胞耐受性。 将含有裸DNA的疫苗制剂注射到预先用能够引起肌纤维凝固性坏死的物质处理的宿主中。

    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences
    6.
    发明授权
    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences 失效
    杂种或嵌合多核苷酸，蛋白质和包含乙型肝炎病毒序列的组合物

    公开(公告)号：US07345026B2

    公开(公告)日：2008-03-18

    申请号：US10388337

    申请日：2003-03-14

    申请人： Hüseyin Firat ,  François Lemonnier ,  Pierre Langlade-Demoyen ,  Marie-Louise Michel ,  Andreas A. Suhrbier

    发明人： Hüseyin Firat ,  François Lemonnier ,  Pierre Langlade-Demoyen ,  Marie-Louise Michel ,  Andreas A. Suhrbier

    IPC分类号： A61K35/00 ,  C12N15/68

    CPC分类号： C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K48/00 ,  A61K2039/5258 ,  A61K2039/57 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2730/10122 ,  C12N2730/10134

    摘要： H-2 class I negative, HLA-A2.1 transgeniic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.

    摘要翻译： 使用H-2 I型阴性，HLA-A2.1转基因HHD小鼠进行HLA-A2.1限制性人肿瘤相关CTL表位的免疫原性的比较评估。 在IFA中注射到小鼠中的这些表位肽之间建立了等级关系，其全局与其结合和稳定HLA-A2.1分子的能力相关。 辅助肽的共注射增强了大多数CTL应答。 相比之下，仍然表达自己的I类分子的经典HLA I类转基因小鼠在大多数情况下并不在相同的实验条件下产生H.A.-A2.1限制性CTL应答。 在HHD小鼠中比较了可接受的临床应用的不同单表位免疫策略。 重组的Ty病毒样颗粒或编码与乙型肝炎病毒中膜包膜蛋白融合的表位的DNA得到最好的结果。 使用后一种方法和基于黑素瘤的多表位构建体，可以在单个动物中同时诱导针对五种不同表位的CTL应答。 因此，HHD小鼠为基于肽的癌症免疫治疗的临床前评估提供了通用的动物模型。

    Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
    9.
    发明授权
    Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis 失效
    核苷酸载体，含有该载体的组合物和用于免疫肝炎的疫苗

    公开(公告)号：US07732423B2

    公开(公告)日：2010-06-08

    申请号：US11978673

    申请日：2007-10-30

    申请人： Marie-Louise Michel ,  Maryline Mancini

    发明人： Marie-Louise Michel ,  Maryline Mancini

    IPC分类号： C07K14/02 ,  C07K14/005 ,  A61K48/00 ,  C12N15/63

    CPC分类号： A61K39/292 ,  A61K39/00 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C12N2730/10122 ,  C12N2730/10134

    摘要： Nucleotide composition containing a vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of the gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers.

    摘要翻译： 含有用于免疫肝炎的载体和疫苗的核苷酸组合物。 包含编码至少一部分病毒的至少一个基因或一个互补DNA的核苷酸载体，以及提供该基因在肌肉细胞中表达的启动子。 该基因可能是乙型肝炎病毒的S基因。 当向甚至慢性HBV携带者施用时的核苷酸载体组合物能够破坏对乙型肝炎病毒的表面抗原的T细胞耐受性。 将含有裸DNA的疫苗制剂注射到预先用能够诱导肌纤维凝固性坏死的物质处理的宿主中。

    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences
    10.
    发明申请
    Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences 审中-公开
    杂种或嵌合多核苷酸，蛋白质和包含乙型肝炎病毒序列的组合物

    公开(公告)号：US20080107693A1

    公开(公告)日：2008-05-08

    申请号：US12004024

    申请日：2007-12-20

    申请人： Huseyin Firat ,  Francois Lemonnier ,  Pierre Langlade-demoyen ,  Marie-Louise Michel ,  Andreas Suhrbier

    发明人： Huseyin Firat ,  Francois Lemonnier ,  Pierre Langlade-demoyen ,  Marie-Louise Michel ,  Andreas Suhrbier

    IPC分类号： A61K39/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P37/04 ,  A61P35/00 ,  C12N15/63

    CPC分类号： C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K48/00 ,  A61K2039/5258 ,  A61K2039/57 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2730/10122 ,  C12N2730/10134

    摘要： H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.

    摘要翻译： 使用H-2级I阴性，HLA-A2.1转基因HHD小鼠进行HLA-A2.1限制性人肿瘤相关CTL表位的免疫原性的比较评估。 在IFA中注射到小鼠中的这些表位肽之间建立了等级关系，其全局与其结合和稳定HLA-A2.1分子的能力相关。 辅助肽的共注射增强了大多数CTL应答。 相比之下，仍然表达自己的I类分子的经典HLA I类转基因小鼠在大多数情况下并不在相同的实验条件下产生H.A.-A2.1限制性CTL应答。 在HHD小鼠中比较了可接受的临床应用的不同单表位免疫策略。 重组的Ty病毒样颗粒或编码与乙型肝炎病毒中膜包膜蛋白融合的表位的DNA得到最好的结果。 使用后一种方法和基于黑素瘤的多表位构建体，可以在单个动物中同时诱导针对五种不同表位的CTL应答。 因此，HHD小鼠为基于肽的癌症免疫治疗的临床前评估提供了通用的动物模型。